Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation

Biotech Giants: A Decade of Cost Efficiency Compared

__timestampGeron CorporationNeurocrine Biosciences, Inc.
Wednesday, January 1, 2014890100014400000
Thursday, January 1, 2015957400033800000
Friday, January 1, 20161469500035900000
Sunday, January 1, 201784370001254000
Monday, January 1, 2018127230004889000
Tuesday, January 1, 2019512720007400000
Wednesday, January 1, 20205005200010100000
Friday, January 1, 202178300014300000
Saturday, January 1, 202286800023200000
Sunday, January 1, 202312374000039700000
Monday, January 1, 202434000000
Loading chart...

In pursuit of knowledge

Cost of Revenue Efficiency: A Tale of Two Biotechs

In the competitive landscape of biotechnology, cost efficiency is paramount. Neurocrine Biosciences, Inc. and Geron Corporation, two prominent players, showcase contrasting strategies in managing their cost of revenue from 2014 to 2023. Neurocrine Biosciences consistently maintained a lower cost of revenue, averaging around $18.5 million annually, with a notable dip in 2017 to just $1.3 million. This reflects a strategic focus on cost containment, possibly due to streamlined operations or strategic partnerships.

Conversely, Geron Corporation's cost of revenue fluctuated significantly, peaking in 2023 with a staggering $123.7 million, a 14-fold increase from its 2021 low. This volatility may indicate aggressive investment in research and development or scaling operations. Understanding these trends offers valuable insights into each company's operational priorities and financial health, crucial for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025